Physician profile
Lycia C Thornburg
NPI 1619904067
$100,227.57
in general payments reported to CMS, 2019-2025
22 companies · $23K in 2025
The $23K reported for 2025 was more than what 94% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $251 · 2020: $1,401 · 2021: $4,730 · 2022: $15K · 2023: $41K · 2024: $15K · 2025: $23K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $30K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $22K · Travel and Lodging: $19K · Food and Beverage: $8,244 · Education: $221.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $30,401.84 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $21,600.00 |
| Travel and Lodging | $18,770.42 |
| Food and Beverage | $8,243.87 |
| Education | $221.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $80,313.98 | 2019-2025 | Botox, Rinvoq, Skyrizi |
| Allergan, INC. | $18,543.12 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $279.13 | 2021-2025 | Dupixent, Libtayo |
| Janssen Biotech, INC. | $170.42 | 2020-2025 | Tremfya |
| Genzyme Corporation | $164.90 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $135.82 | 2022-2025 | Spevigo |
| Galderma Laboratories, L.P. | $119.72 | 2019-2025 | Nemluvio |
| E.R. Squibb & Sons, L.L.C. | $115.02 | 2022-2025 | Sotyktu |
| Lilly USA, LLC | $53.62 | 2019-2025 | Ebglyss |
| Ucb, INC. | $51.94 | 2019-2021 | |
| Amgen INC. | $47.54 | 2025 | Otezla |
| Kyowa Kirin, INC. | $41.76 | 2023-2024 | Poteligeo |
| Novartis Pharmaceuticals Corporation | $33.27 | 2020 | |
| Janssen Scientific Affairs, LLC | $32.63 | 2024 | Tremfya |
| Vyne Pharmaceuticals INC. | $18.46 | 2020 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $17.63 | 2025 | Zoryve |
| Organon LLC | $17.55 | 2024 | |
| Leo Pharma INC. | $17.23 | 2025 | Spevigo |
| Sun Pharmaceutical Industries INC. | $15.18 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $14.56 | 2019 | |
| Merck Sharp & Dohme LLC | $13.12 | 2019 | |
| Pfizer INC. | $10.97 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lycia Thornburg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.